1-N-丁基乙内酰脲 | 33599-32-5

• 物质功能分类: 化学试剂 - 有机试剂 - 脲
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 1-N-丁基乙内酰脲
• 中文别名: 1-丁乙内酰脲；1-丁基-2,4-二氧代咪唑啉；1-丁基乙内酰脲
• 英文名称: 1-butylhydantoin
• 英文别名: 1-Butylimidazolidine-2,4-dione
• CAS: 33599-32-5
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.184
• InChiKey: NOHNSECEKFOVGT-UHFFFAOYSA-N

物化性质

• 熔点：
  94°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

SDS

1-Butylhydantoin Revision number: 1
SAFETY DATA SHEET

---

Section 1. BASE INFORMATION
Product name: 1-Butylhydantoin

Revision number: 1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the GHS
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS Not classified
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements
None
Pictograms or hazard symbols
Signal word No signal word
None
Hazard statement
Precautionary statements None

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Component(s): 1-Butylhydantoin
Percent: >98.0%(T)
CAS Number: 33599-32-5
Synonyms: 1-Butyl-2,4-dioxoimidazolidine
Chemical Formula: C7H12N2O2

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards: Take care as it may decompose upon combustion or in high temperatures to
generate poisonous fume.
1-Butylhydantoin

---

Section 5. FIRE-FIGHTING MEASURES
Specific methods: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Use personal protective equipment. Keep people away from and upwind of spill/leak.
Personal precautions,
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Handling
Handling is performed in a well ventilated place. Wear suitable protective equipment.
Technical measures:
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Storage
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Law is followed.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: crystal - powder
Color: White - Almost white
Odor: No data available
pH: No data available
Melting point/freezing point:94 °C
Boiling Point/Range: No data available
Flash Point: No data available
Explosive limits
Lower: No data available
Upper: No data available
Density: No data available
Solubility: No data available

---

Section 10. STABILITY AND REACTIVITY
Stability: Stable under proper conditions.
Reactivity: No special reactivity has been reported.
Incompartible materials: oxidizing agents
1-Butylhydantoin

---

Section 10. STABILITY AND REACTIVITY
Hazardous Decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx)
Products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
NTP = No data available
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
No data available
Fish:
Crustacea: No data available
No data available
Algae:
Persistence / degradability: No data available
No data available
Bioaccumulative
potential(BCF):
Mobillity in soil
log Pow: No data available
No data available
Soil adsorption (Koc):
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
Not Listed
UN-No:

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26,
2002): Safe use and production, the storage of a dangerous chemical, transport, loading and unloading were
prescribed.
1-Butylhydantoin

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-N-丁基乙内酰脲 在 溴 、 sodium hydride 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 33.75h， 生成 1-Butyl-5-[1-{2-butyl-3-[4-(2-trityl-2H-tetrazol-5-yl)-benzyl]-3H-imidazol-4-yl}-meth-(Z)-ylidene]-imidazolidine-2,4-dione
  参考文献：
  名称：

  5-[[1-（4'-羧基苄基）咪唑基]亚甲基]乙内酰脲衍生物作为口服活性血管紧张素II受体拮抗剂。

  摘要：

  已经制备了一系列5-[[[1-（4'-羧基苄基）咪唑基]亚甲基]乙内酰脲，并作为体内和体外血管紧张素II（Ang II）拮抗剂进行了评估。乙内酰脲环上取代基的变化导致有效的和选择性的Ang II拮抗剂，在AT1受体具有纳摩尔IC50值，对AT2受体的亲和力可忽略不计。优选的取代基包括在R1上的正丁基和在R2上的烷基或杂芳基甲基取代基。R2取代基的选择部分取决于其log P的计算，因为在CLOGP和AT1结合亲和力之间观察到显着相关性。许多AT1拮抗剂共有的联苯四唑药效基团可以被例如4-碳甲氧基苯基取代基取代，从而在体外和体内产生有效的Ang II拮抗剂。该系列的代表性化合物是57，它在30 mg / kg po下使肾性高血压大鼠的平均动脉血压降低40％，在10 mg / kg po时降低25％。另外，该化合物在缺盐的正常血压猴子模型中有效，在口服10 mg / kg时最大降低血压27％。总之，这些化合物属于一类新的Ang

  DOI：

  10.1021/jm00019a005
• 作为产物：
  描述：

  乙基N-丁基甘氨酸酯 以 盐酸 、 乙醇 、 水 为溶剂， 以68%的产率得到1-N-丁基乙内酰脲
  参考文献：
  名称：

  Substituted-5-methylidene hydantoins with AT.sub.1 receptor antagonist

  摘要：

  揭示了1-苄基咪唑-5-甲基亚咪唑烷酮的替代物，以及制备它们的方法，含有它们的药物组合物，以及使用它们的方法。还揭示了在制备本发明化合物中有用的中间体，以及制备新中间体的合成方法。这些化合物可用作抗血管紧张素II的拮抗剂，因此在控制高血压、高醛固酮症、充血性心力衰竭、手术诱导的血管平滑肌增生和青光眼方面是有用的。

  公开号：

  US05308853A1

文献信息

• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2018183781A1

  公开（公告）日：2018-10-04

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

  提供的是化合物、包含该化合物的药物组合物、制备该化合物的方法，以及使用该化合物和组合物治疗与电压门控钠通道功能相关的病症的方法，其中所述化合物是根据公式(I)的11,13-修饰的石房蛤毒素：其中R4、R4a、R7、R7a和X2如本文所述。
• 5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line
  作者：Valentina Zuliani、Caterina Carmi、Mirko Rivara、Marco Fantini、Alessio Lodola、Federica Vacondio、Fabrizio Bordi、Pier Vincenzo Plazzi、Andrea Cavazzoni、Maricla Galetti、Roberta R. Alfieri、Pier Giorgio Petronini、Marco Mor

  DOI：10.1016/j.ejmech.2009.01.035

  日期：2009.9

  substituents, was found to be the most active derivative of the series. It inhibited EGFR autophosphorylation and induced DNA damage in A549 cells. Compound 7 and other synthesized 5-benzylidene hydantoin derivatives increased p53 levels, suggesting that the dual mechanism of action was a common feature shared by compound 7 and other member of the series.

  最近有报道称苄基乙内酰脲是一类新的EGFR抑制剂。我们在这里描述一种简单有效的方法，用于并行溶液相合成5-亚苄基乙内酰脲的文库，该文库对人肺腺癌A549细胞系的抗增殖活性进行了评估。检查了乙内酰脲核上1、3和5位的各种取代基。在位置1处有5-亚苄基和亲脂性取代基的情况下，大多数受试化合物均以20μM的浓度抑制细胞增殖。带有1-苯乙基和（E）-5- p的化合物7（UPR1024）发现-OH-亚苄基取代基是该系列中活性最高的衍生物。它抑制EGFR自磷酸化并诱导A549细胞中的DNA损伤。化合物7和其他合成的5-亚苄基乙内酰脲衍生物增加了p53的含量，表明双重作用机制是化合物7和该系列其他成员共有的共同特征。
• Substituted-5-methylidene hydantoins with AT.sub.1 receptor antagonist
  申请人：Warner-Lambert Company

  公开号：US05308853A1

  公开（公告）日：1994-05-03

  Substituted 1-benzylimidazole-5-methylidene hydantoins are disclosed as well as methods of preparing them, pharmaceutical compositions containing them, and method of using them. Intermediates useful in the preparation of the compounds of the invention are also disclosed and synthetic methods for preparing the novel intermediates. The compounds are useful as antagonists of angiotensin II and thus are useful in the control of hypertension, hyperaldosteronism, congestive heart failure, surgically induced vascular smooth muscle proliferation, and glaucoma.

  揭示了1-苄基咪唑-5-甲基亚咪唑烷酮的替代物，以及制备它们的方法，含有它们的药物组合物，以及使用它们的方法。还揭示了在制备本发明化合物中有用的中间体，以及制备新中间体的合成方法。这些化合物可用作抗血管紧张素II的拮抗剂，因此在控制高血压、高醛固酮症、充血性心力衰竭、手术诱导的血管平滑肌增生和青光眼方面是有用的。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES MODIFIÉES 11,13 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2020072835A1

  公开（公告）日：2020-04-09

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

  本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法，以及在治疗与电压门控钠通道功能相关的疾病中使用该化合物和组合物的方法，其中该化合物是根据式(I)的11,13-修饰沙雌毒素：(式(I))；其中R1和R2如本文所述。
• 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
  申请人：Pharmacia Italia, SpA

  公开号：US06765003B1

  公开（公告）日：2004-07-20

  Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO—NH— or HO—, R1 is selected from phenyl, 4-chlorophenyl, 4-florophenyl, 4-cyanophenyl, benzamido (i.e., —NH—CO-Ph) and benzamido substituted on the terminal phenyl ring by C1-C4 alkyl, fluoro, chloro, cyano or C1-4 alkoxy; R2 is selected from (a) —S—Ar or —S—CH2—Ar wherein Ar is an aromatic moiety; (b) —O—Ar wherein Ar is as defined above; (c) —S-Het or —S—CH2-Het wherein Het is a heterocyclic ring; and (d) 2,5-dioxo-1-imidazolidinyl or 2,4-dioxo-1-imidazolinyl; and the pharmaceutically acceptable salts thereof; have potent and selective inhibitory activity against matrix metalloproteinases (MMPs) and can thus be used in the treatment and prevention of diseases mediated by MMPs.

  化合物是公式(I)的3-芳基磺酰基-2-甲基丙烯酸衍生物，其中X为HO—NH—或HO—，R1从苯基、4-氯苯基、4-氟苯基、4-氰苯基、苯甲酰氨基（即，—NH—CO-Ph）和苯甲酰氨基中选择，其在末端苯环上被C1-C4烷基、氟、氯、氰或C1-4烷氧基取代；R2从(a) —S—Ar或—S—CH2—Ar中选择，其中Ar是芳香基；(b) —O—Ar，其中Ar如上所定义；(c) —S-Het或—S—CH2-Het，其中Het是杂环环；和(d) 2,5-二氧杂-1-咪唑烷基或2,4-二氧杂-1-咪唑烷基；以及其药学上可接受的盐；具有对基质金属蛋白酶（MMPs）具有强效和选择性抑制活性，因此可用于治疗和预防由MMPs介导的疾病。